In addition, relatlimab, a novel ICI targeting the LAG-3, was shown to have an ORR of 12.0% when combined with nivolumab in melanoma previously treated with anti-PD-(L)1, according to the phase I/IIa RELATIVITY-020 trial [23]. Here, LAG3 is linked to melanoma.